Galapagos announces natural compounds collaboration with LEO Pharma
Galapagos NV announced a first collaboration with privately-held LEO Pharma. BioFocus DPI, Galapagos' service division, will use a subset of its natural compound collection for high throughput screening, hit verification, and profiling of selected compounds for LEO Pharma's antibacterial research program. In return, Galapagos stands to receive up to EUR400,000 in project fees and up to EUR3 million in milestone payments. Galapagos may also receive royalties on sales of commercial products resulting from the collaboration.
The agreement with LEO Pharma marks Galapagos' first for its natural compound collection, acquired with the drug discovery activities of Discovery Partners International in July 2006. It focuses on the discovery of new antibacterial agents using specific targeted screens. Screens for new antibiotics are particularly appropriate for natural product discovery.
Other news from the department business & finance
